AFF1 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 7 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain ALK status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

BCL2 is altered in 42.86% of high grade B-cell lymphoma, not otherwise specified patients [2].

BCL2 is an inclusion eligibility criterion in 22 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 21 are open and 1 is closed. Of the trials that contain BCL2 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].

BCL6 is an inclusion eligibility criterion in 22 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 21 are open and 1 is closed. Of the trials that contain BCL6 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].

CD274 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 2 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KMT2A is altered in 14.29% of high grade B-cell lymphoma, not otherwise specified patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is altered in 42.86% of high grade B-cell lymphoma, not otherwise specified patients [2].

MYC is an inclusion eligibility criterion in 22 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 21 are open and 1 is closed. Of the trials that contain MYC status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [3].